Cubist Pharmaceuticals Inc. Sets New 1-Year High at $74.44 (CBST)
Cubist Pharmaceuticals (NASDAQ:CBST) set a new 52-week high during trading on Monday, Analyst RN reports. The stock traded as high as $74.44 and last traded at $73.03, with a volume of 1,739,817 shares. The stock had previously closed at $70.01.
Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Cubist Pharmaceuticals in a research note to investors on Friday, December 27th. They now have a $70.00 price target on the stock. Separately, analysts at RBC Capital raised their price target on shares of Cubist Pharmaceuticals from $78.00 to $82.00 in a research note to investors on Friday, December 20th. They now have an “outperform” rating on the stock. Finally, analysts at Cantor Fitzgerald raised their price target on shares of Cubist Pharmaceuticals from $63.00 to $65.00 in a research note to investors on Tuesday, December 17th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and eight have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $68.07.
In other Cubist Pharmaceuticals news, Director Kenneth Bate sold 10,000 shares of the stock in a transaction dated Thursday, January 9th. The shares were sold at an average price of $70.00, for a total transaction of $700,000.00. Following the sale, the director now directly owns 7,914 shares in the company, valued at approximately $553,980. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Cubist Pharmaceuticals has a 52-week low of $40.44 and a 52-week high of $72.64. The stock’s 50-day moving average is $66.70 and its 200-day moving average is $62.50. The company has a market cap of $5.422 billion and a price-to-earnings ratio of 181.84.
Cubist Pharmaceuticals (NASDAQ:CBST) last released its earnings data on Thursday, October 17th. The company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.07. The company had revenue of $266.00 million for the quarter, compared to the consensus estimate of $267.96 million. During the same quarter in the previous year, the company posted $0.55 earnings per share. The company’s revenue for the quarter was up 11.7% on a year-over-year basis. Analysts expect that Cubist Pharmaceuticals will post $-0.07 EPS for the current fiscal year.
Cubist Pharmaceuticals, Inc (NASDAQ:CBST) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.